Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medexus Pharmaceuticals Inc MEDXF


Primary Symbol: T.MDP

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.


TSX:MDP - Post by User

Comment by GoldenArmon Aug 03, 2021 2:47pm
150 Views
Post# 33643066

RE:RE:RE:RE:RE:RE:MEDXF gets CRL

RE:RE:RE:RE:RE:RE:MEDXF gets CRLIf you had 100% safe cure for cancer FDA would reject it because they look at how it would effect big pharma. Why the road block to list on Nasdaq? Who was pulling strings in the background to keep MDP off the Nasdaq?

Here is what Ken said

"

"In the fourth quarter of fiscal 2021, IXINITY sales declined as pharmacy and wholesale customers worked through inventory on hand. In addition, an unexpected manufacturing expense related to the Pediatric Trial of IXINITY impacted our Adjusted EBITDA. We do not expect this issue to affect the timing for completion of the trial. With a goal of long-term margin improvement, we are working with our manufacturing partners to improve the supply chain and manufacturing process in order to meet the unit demand for IXINITY, which grew by more than 15% in the year-ended March 31, 2021."

"We continue to evaluate significant in-licensing opportunities that we believe will enable us to further leverage our North American infrastructure. During the year we strengthened our business development team and sharpened our focus on US centric opportunities. This means an increased focus on Rare, Orphan, and Autoimmune disease. As part of our growth strategy, we were pleased to announce an uplisting to the TSX earlier this week. We believe that a listing on a Tier 1 exchange will also help maximize value for our shareholders and increase our profile and liquidity in the market. Additionally, we are confident that graduating to a senior exchange will provide us with access to a broader range of institutional shareholders. We will continue to evaluate the timing of a dual-listing on the Nasdaq as we advance several ongoing business initiatives."

This FDA decision stinks and they have no basis for their conclusion.

<< Previous
Bullboard Posts
Next >>